Image Place holder

Richard Pratley, MD, PhD

Overview


Associations

    • Cancer Biology and Evolution Program

Education & Training

Publications

  • Pratley RE, Jacob S, Baek S, Trautmann ME, Hompesch M, Han O, Stewart J, Sorli CH, Shaunik A, Yoon KH. Efficacy and safety of efpeglenatide in key patient subgroups from the BALANCE randomized trial, stratified by pre-diabetes status, BMI, and age at baseline. BMJ Open Diabetes Res Care. 2022 Jan.10(1). Pubmedid: 35042751. Pmcid: PMC8768911.
  • Cherney DZI, Cosentino F, Dagogo-Jack S, McGuire DK, Pratley R, Frederich R, Maldonado M, Liu CC, Liu J, Pong A, Cannon CP. Ertugliflozin and Slope of Chronic eGFR: Prespecified Analyses from the Randomized VERTIS CV Trial. Clin J Am Soc Nephrol. 2021 Sep.16(9):1345-1354. Pubmedid: 34497110. Pmcid: PMC8729577.
  • Gerstein HC, Sattar N, Rosenstock J, Ramasundarahettige C, Pratley R, Lopes RD, Lam CSP, Khurmi NS, Heenan L, Del Prato S, Dyal L, Branch K. Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes. N Engl J Med. 2021 Sep.385(10):896-907. Pubmedid: 34215025.
  • Sattar N, Lee MMY, Kristensen SL, Branch KRH, Del Prato S, Khurmi NS, Lam CSP, Lopes RD, McMurray JJV, Pratley RE, Rosenstock J, Gerstein HC. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials. Lancet Diabetes Endocrinol. 2021 Oct.9(10):653-662. Pubmedid: 34425083.
  • Dagogo-Jack S, Pratley RE, Cherney DZI, McGuire DK, Cosentino F, Shih WJ, Liu J, Frederich R, Mancuso JP, Raji A, Gantz I. Glycemic efficacy and safety of the SGLT2 inhibitor ertugliflozin in patients with type 2 diabetes and stage 3 chronic kidney disease: an analysis from the VERTIS CV randomized trial. BMJ Open Diabetes Res Care. 2021 Oct.9(1). Pubmedid: 34620621. Pmcid: PMC8499340.
  • Pratley RE, Catarig AM, Lingvay I, Viljoen A, Paine A, Lawson J, Chubb B, Gorst-Rasmussen A, Miresashvili N. An indirect treatment comparison of the efficacy of semaglutide 1.0 mg versus dulaglutide 3.0 and 4.5 mg. Diabetes Obes Metab. 2021 Nov.23(11):2513-2520. Pubmedid: 34286894.
  • Lam CSP, Ramasundarahettige C, Branch KRH, Sattar N, Rosenstock J, Pratley R, Del Prato S, Lopes RD, Niemoeller E, Khurmi NS, Baek S, Gerstein HC. Efpeglenatide and Clinical Outcomes with and without Concomitant Sodium-Glucose Co-Transporter-2 Inhibition Use in Type 2 Diabetes: Exploratory Analysis of the AMPLITUDE-O Trial. Circulation. 2021 Nov. Pubmedid: 34775781.
  • Klein KR, Franek E, Marso S, Pieber TR, Pratley RE, Gowda A, Kvist K, Buse JB. Hemoglobin glycation index, calculated from a single fasting glucose value, as a prediction tool for severe hypoglycemia and major adverse cardiovascular events in DEVOTE. BMJ Open Diabetes Res Care. 2021 Nov.9(2). Pubmedid: 34819298. Pmcid: PMC8614152.
  • Carlson AL, Kanapka LG, Miller KM, Ahmann AJ, Chaytor NS, Fox S, Kiblinger L, Kruger D, Levy CJ, Peters AL, Rickels MR, Salam M, Shah VN, Young LA, Kudva YC, Pratley R. Hypoglycemia and Glycemic Control in Older Adults With Type 1 Diabetes: Baseline Results From the WISDM Study. J Diabetes Sci Technol. 2021 May.15(3):582-592. Pubmedid: 31867988. Pmcid: PMC8120041.
  • Cherney DZI, Charbonnel B, Cosentino F, Dagogo-Jack S, McGuire DK, Pratley R, Shih WJ, Frederich R, Maldonado M, Pong A, Cannon CP. Effects of ertugliflozin on kidney composite outcomes, renal function and albuminuria in patients with type 2 diabetes mellitus: an analysis from the randomised VERTIS CV trial. Diabetologia. 2021 Jun.64(6):1256-1267. Pubmedid: 33665685. Pmcid: PMC8099851.
  • Vendrame F, Calhoun P, Bocchino LE, Pratley RE, Casu A. Impact of bariatric surgery and weight loss medications in adults with type 1 diabetes in the T1D Exchange Clinic Registry. J Diabetes Complicat. 2021 Jun.35(6):107884. Pubmedid: 33610436.
  • Buse JB, Holst I, Knop FK, Kvist K, Thielke D, Pratley R. Prototype of an evidence-based tool to aid individualized treatment for type 2 diabetes. Diabetes Obes Metab. 2021 Jul.23(7):1666-1671. Pubmedid: 33764641. Pmcid: PMC8251774.
  • Espeland MA, Pratley RE, Rosenstock J, Kadowaki T, Seino Y, Zinman B, Marx N, McGuire DK, Andersen KR, Mattheus M, Keller A, Weber M, Johansen OE. Cardiovascular outcomes and safety with linagliptin, a dipeptidyl peptidase-4 inhibitor, compared with the sulphonylurea glimepiride in older people with type 2 diabetes: A subgroup analysis of the randomized CAROLINA trial. Diabetes Obes Metab. 2021 Feb.23(2):569-580. Pubmedid: 33185002. Pmcid: PMC7839453.
  • Gerstein HC, Branch K, Heenan L, Del Prato S, Khurmi NS, Lam CSP, Pratley R, Rosenstock J, Sattar N. Design and baseline characteristics of the AMPLITUDE-O cardiovascular outcomes trial of efpeglenatide, a weekly glucagon-like peptide-1 receptor agonist. Diabetes Obes Metab. 2021 Feb.23(2):318-323. Pubmedid: 33026143.
  • McGuire DK, Shih WJ, Cosentino F, Charbonnel B, Cherney DZI, Dagogo-Jack S, Pratley R, Greenberg M, Wang S, Huyck S, Gantz I, Terra SG, Masiukiewicz U, Cannon CP. Association of SGLT2 Inhibitors With Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes: A Meta-analysis. JAMA Cardiol. 2021 Feb.6(2):148-158. Pubmedid: 33031522. Pmcid: PMC7542529.
  • Cherney DZI, McGuire DK, Charbonnel B, Cosentino F, Pratley R, Dagogo-Jack S, Frederich R, Maldonado M, Liu J, Pong A, Liu CC, Cannon CP. Gradient of Risk and Associations With Cardiovascular Efficacy of Ertugliflozin by Measures of Kidney Function: Observations From VERTIS CV. Circulation. 2021 Feb.143(6):602-605. Pubmedid: 33186063.
  • Serrano J, Seflova J, Park J, Pribadi M, Sanematsu K, Shigemura N, Serna V, Yi F, Mari A, Procko E, Pratley RE, Robia SL, Kyriazis GA. The Ile191Val is a partial loss-of-function variant of the TAS1R2 sweet-taste receptor and is associated with reduced glucose excursions in humans. Mol Metab. 2021 Dec.54:101339. Pubmedid: 34509698. Pmcid: PMC8476773.
  • Lingvay I, Bauer R, Baker-Knight J, Lawson J, Pratley R. An indirect treatment comparison of semaglutide 2.0 mg versus dulaglutide 3.0 mg and 4.5 mg using multilevel network meta-regression. J Clin Endocrinol Metab. 2021 Dec. Pubmedid: 34922383.
  • Thethi TK, Bilal A, Pratley RE. Cardiovascular Outcomes Trials of Incretin-Based Therapies. Diabetes Spectr. 2021 Aug.34(3):217-224. Pubmedid: 34511847. Pmcid: PMC8387616.
  • Kim SH, Brodsky IG, Chatterjee R, Kashyap SR, Knowler WC, Liao E, Nelson J, Pratley R, Rasouli N, Vickery EM, Sarnak M, Pittas AG. Effect of Vitamin D Supplementation on Kidney Function in Adults with Prediabetes: A Secondary Analysis of a Randomized Trial. Clin J Am Soc Nephrol. 2021 Aug.16(8):1201-1209. Pubmedid: 34362787. Pmcid: PMC8455038.
  • Cherney DZI, Dagogo-Jack S, McGuire DK, Cosentino F, Pratley R, Shih WJ, Frederich R, Maldonado M, Liu J, Wang S, Cannon CP. Kidney outcomes using a sustained ≥40% decline in eGFR: A meta-analysis of SGLT2 inhibitor trials. Clin Cardiol. 2021 Aug.44(8):1139-1143. Pubmedid: 34129237. Pmcid: PMC8364727.
  • Persson F, Bain SC, Mosenzon O, Heerspink HJL, Mann JFE, Pratley R, Raz I, Idorn T, Rasmussen S, von Scholten BJ, Rossing P. Changes in Albuminuria Predict Cardiovascular and Renal Outcomes in Type 2 Diabetes: A Post Hoc Analysis of the LEADER Trial. Diabetes Care. 2021 Apr.44(4):1020-1026. Pubmedid: 33504496. Pmcid: PMC7985419.
  • Leiter LA, Bain SC, Bhatt DL, Buse JB, Mazer CD, Pratley RE, Rasmussen S, Ripa MS, Vrazic H, Verma S. The effect of glucagon-like peptide-1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across baseline blood pressure categories: Analysis of the LEADER and SUSTAIN 6 trials. Diabetes Obes Metab. 2020 Sep.22(9):1690-1695. Pubmedid: 32372454. Pmcid: PMC7496251.
  • Munshi MN, Meneilly GS, Rodríguez-Mañas L, Close KL, Conlin PR, Cukierman-Yaffe T, Forbes A, Ganda OP, Kahn CR, Huang E, Laffel LM, Lee CG, Lee S, Nathan DM, Pandya N, Pratley R, Gabbay R, Sinclair AJ. Diabetes in ageing: pathways for developing the evidence base for clinical guidance. Lancet Diabetes Endocrinol. 2020 Oct.8(10):855-867. Pubmedid: 32946822. Pmcid: PMC8223534.
  • Shah VN, Bailey R, Wu M, Foster NC, Pop-Busui R, Katz M, Crandall J, Bacha F, Nadeau K, Libman I, Hiers P, Mizokami-Stout K, DiMeglio LA, Sherr J, Pratley R, Agarwal S, Snell-Bergeon J, Cengiz E, Polsky S, Mehta SN. Risk Factors for Cardiovascular Disease (CVD) in Adults with Type 1 Diabetes: Findings from Prospective Real-life T1D Exchange Registry. J Clin Endocrinol Metab. 2020 May.105(5). Pubmedid: 31955209. Pmcid: PMC7341163.
  • Pratley RE, Kanapka LG, Rickels MR, Ahmann A, Aleppo G, Beck R, Bhargava A, Bode BW, Carlson A, Chaytor NS, Fox DS, Goland R, Hirsch IB, Kruger D, Kudva YC, Levy C, McGill JB, Peters A, Philipson L, Philis-Tsimikas A, Pop-Busui R, Shah VN, Thompson M, Vendrame F, Verdejo A, Weinstock RS, Young L, Miller KM. Effect of Continuous Glucose Monitoring on Hypoglycemia in Older Adults With Type 1 Diabetes: A Randomized Clinical Trial. Jama. 2020 Jun.323(23):2397-2406. Pubmedid: 32543682. Pmcid: PMC7298607.
  • Cosentino F, Cannon CP, Cherney DZI, Masiukiewicz U, Pratley R, Dagogo-Jack S, Frederich R, Charbonnel B, Mancuso J, Shih WJ, Terra SG, Cater NB, Gantz I, McGuire DK. Efficacy of Ertugliflozin on Heart Failure-Related Events in Patients With Type 2 Diabetes Mellitus and Established Atherosclerotic Cardiovascular Disease: Results of the VERTIS CV Trial. Circulation. 2020 Dec.142(23):2205-2215. Pubmedid: 33026243. Pmcid: PMC7717477.
  • Igudesman D, Crandell J, Zhong VW, Cristello Sarteau A, Kahkoska AR, Corbin K, Pratley R, Kosorok MR, Maahs DM, Mayer-Davis EJ. Dietary intake on days with and without hypoglycemia in youth with type 1 diabetes: The Flexible Lifestyle Empowering Change trial. Pediatr Diabetes. 2020 Dec.21(8):1475-1484. Pubmedid: 32981192.
  • Heller S, Lingvay I, Marso SP, Philis-Tsimikas A, Pieber TR, Poulter NR, Pratley RE, Hachmann-Nielsen E, Kvist K, Lange M, Moses AC, Trock Andresen M, Buse JB. Development of a hypoglycaemia risk score to identify high-risk individuals with advanced type 2 diabetes in DEVOTE. Diabetes Obes Metab. 2020 Dec.22(12):2248-2256. Pubmedid: 32996693. Pmcid: PMC7756403.
  • Heller S, Lingvay I, Marso SP, Philis-Tsimikas A, Pieber TR, Poulter NR, Pratley RE, Hachmann-Nielsen E, Kvist K, Lange M, Moses AC, Andresen MT, Buse JB. Risk of severe hypoglycaemia and its impact in type 2 diabetes in DEVOTE. Diabetes Obes Metab. 2020 Dec.22(12):2241-2247. Pubmedid: 32250536. Pmcid: PMC7754351.
  • Sinclair AJ, Heller SR, Pratley RE, Duan R, Heine RJ, Festa A, Kiljański J. Evaluating glucose-lowering treatment in older people with diabetes: Lessons from the IMPERIUM trial. Diabetes Obes Metab. 2020 Aug.22(8):1231-1242. Pubmedid: 32100382. Pmcid: PMC7383926.
  • Mizokami-Stout KR, Li Z, Foster NC, Shah V, Aleppo G, McGill JB, Pratley R, Toschi E, Ang L, Pop-Busui R. The Contemporary Prevalence of Diabetic Neuropathy in Type 1 Diabetes: Findings From the T1D Exchange. Diabetes Care. 2020 Apr.43(4):806-812. Pubmedid: 32029635. Pmcid: PMC7085805.
  • Rickels MR, Evans-Molina C, Bahnson HT, Ylescupidez A, Nadeau KJ, Hao W, Clements MA, Sherr JL, Pratley RE, Hannon TS, Shah VN, Miller KM, Greenbaum CJ. High residual C-peptide likely contributes to glycemic control in type 1 diabetes. J Clin Invest. 2020 Apr.130(4):1850-1862. Pubmedid: 31895699. Pmcid: PMC7108933.
  • Addala A, Igudesman D, Kahkoska AR, Muntis FR, Souris KJ, Whitaker KJ, Pratley RE, Mayer-Davis E. The interplay of type 1 diabetes and weight management: A qualitative study exploring thematic progression from adolescence to young adulthood. Pediatr Diabetes. 2019 Nov.20(7):974-985. Pubmedid: 31392807. Pmcid: PMC7196280.
  • Pittas AG, Dawson-Hughes B, Sheehan P, Ware JH, Knowler WC, Aroda VR, Brodsky I, Ceglia L, Chadha C, Chatterjee R, Desouza C, Dolor R, Foreyt J, Fuss P, Ghazi A, Hsia DS, Johnson KC, Kashyap SR, Kim S, LeBlanc ES, Lewis MR, Liao E, Neff LM, Nelson J, O'Neil P, Park J, Peters A, Phillips LS, Pratley R, Raskin P, Rasouli N, Robbins D, Rosen C, Vickery EM, Staten M. Vitamin D Supplementation and Prevention of Type 2 Diabetes. N Engl J Med. 2019 Aug.381(6):520-530. Pubmedid: 31173679. Pmcid: PMC6993875.
  • Wolk R, Bertolet M, Brooks MM, Pratley RE, Sobel BE, Frye RL, Singh P, Calvin AD, Rutter MK, Mooradian AD, Somers VK. Differential effects of insulin sensitization and insulin provision treatment strategies on concentrations of circulating adipokines in patients with diabetes and coronary artery disease in the BARI 2D trial. Eur J Prev Cardiol. 2016 Jan.23(1):50-58. Pubmedid: 25073857. Pmcid: PMC4385003.
  • Kyriazis GA, Smith KR, Tyrberg B, Hussain T, Pratley RE. Sweet taste receptors regulate basal insulin secretion and contribute to compensatory insulin hypersecretion during the development of diabetes in male mice. Endocrinology. 2014 Jun.155(6):2112-2121. Pubmedid: 24712876. Pmcid: PMC4020927.
  • Pratley RE. Linagliptin use in older individuals with type 2 diabetes. Clin Interv Aging. 2014 Jul.9:1109-1114. Pubmedid: 25083132. Pmcid: PMC4108453.
  • Pratley RE. The efficacy and effectiveness of drugs for diabetes: how do clinical trials and the real world compare?. Diabetologia. 2014 Jul.57(7):1273-1275. Pubmedid: 24849569.
  • Weissman PN, Carr MC, Ye J, Cirkel DT, Stewart M, Perry C, Pratley R. HARMONY 4: randomised clinical trial comparing once-weekly albiglutide and insulin glargine in patients with type 2 diabetes inadequately controlled with metformin with or without sulfonylurea. Diabetologia. 2014 Dec.57(12):2475-2484. Pubmedid: 25208756.
  • Jumpertz R, Guijarro A, Pratley RE, Mason CC, Piomelli D, Krakoff J. Associations of fatty acids in cerebrospinal fluid with peripheral glucose concentrations and energy metabolism. PLoS One. 2013 Feb.7(7):e41503. Pubmedid: 22911803. Pmcid: PMC3404019.
  • Pratley RE, Nauck MA, Bailey T, Montanya E, Filetti S, Garber AJ, Thomsen AB, Furber S, Davies M. Efficacy and safety of switching from the DPP-4 inhibitor sitagliptin to the human GLP-1 analog liraglutide after 52 weeks in metformin-treated patients with type 2 diabetes: a randomized, open-label trial. Diabetes Care. 2012 Oct.35(10):1986-1993. Pubmedid: 22851600. Pmcid: PMC3447855.
  • Sideleva O, Suratt BT, Black KE, Tharp WG, Pratley RE, Forgione P, Dienz O, Irvin CG, Dixon AE. Obesity and asthma: an inflammatory disease of adipose tissue not the airway. Am J Respir Crit Care Med. 2012 Oct.186(7):598-605. Pubmedid: 22837379. Pmcid: PMC3480522.
  • Kirkman MS, Briscoe VJ, Clark N, Florez H, Haas LB, Halter JB, Huang ES, Korytkowski MT, Munshi MN, Odegard PS, Pratley RE, Swift CS. Diabetes in older adults: a consensus report. J Am Geriatr Soc. 2012 Dec.60(12):2342-2356. Pubmedid: 23106132. Pmcid: PMC4525769.
  • Kirkman MS, Briscoe VJ, Clark N, Florez H, Haas LB, Halter JB, Huang ES, Korytkowski MT, Munshi MN, Odegard PS, Pratley RE, Swift CS. Diabetes in older adults. Diabetes Care. 2012 Dec.35(12):2650-2664. Pubmedid: 23100048. Pmcid: PMC3507610.
  • Tharp WG, Lee YH, Greene SM, Vincellete E, Beach TG, Pratley RE. Measurement of altered AβPP isoform expression in frontal cortex of patients with Alzheimer's disease by absolute quantification real-time PCR. J Alzheimers Dis. 2012 Apr.29(2):449-457. Pubmedid: 22258516. Pmcid: PMC3325610.
  • Dixon AE, Pratley RE, Forgione PM, Kaminsky DA, Whittaker-Leclair LA, Griffes LA, Garudathri J, Raymond D, Poynter ME, Bunn JY, Irvin CG. Effects of obesity and bariatric surgery on airway hyperresponsiveness, asthma control, and inflammation. J Allergy Clin Immun. 2011 Sep.128(3):508-15.e1. Pubmedid: 21782230. Pmcid: PMC3164923.
  • Jumpertz R, Guijarro A, Pratley RE, Piomelli D, Krakoff J. Central and peripheral endocannabinoids and cognate acylethanolamides in humans: association with race, adiposity, and energy expenditure. J Clin Endocrinol Metab. 2011 Mar.96(3):787-791. Pubmedid: 21177788. Pmcid: PMC3047230.
  • Villa J, Pratley RE. Adipose tissue dysfunction in polycystic ovary syndrome. Curr Diab Rep. 2011 Jun.11(3):179-184. Pubmedid: 21424395.
  • Schneider A, Pratley RE. Does the metabolic syndrome carry additional risk for myocardial infarction?. Curr Diab Rep. 2011 Jun.11(3):149-150. Pubmedid: 21336844.
  • Power M, Pratley R. Alternative and complementary treatments for metabolic syndrome. Curr Diab Rep. 2011 Jun.11(3):173-178. Pubmedid: 21336843.
  • Sobel BE, Hardison RM, Genuth S, Brooks MM, McBane RD, Schneider DJ, Pratley RE, Huber K, Wolk R, Krishnaswami A, Frye RL. Profibrinolytic, antithrombotic, and antiinflammatory effects of an insulin-sensitizing strategy in patients in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial. Circulation. 2011 Aug.124(6):695-703. Pubmedid: 21768545. Pmcid: PMC4220292.
  • Jaworski DM, Sideleva O, Stradecki HM, Langlois GD, Habibovic A, Satish B, Tharp WG, Lausier J, Larock K, Jetton TL, Peshavaria M, Pratley RE. Sexually dimorphic diet-induced insulin resistance in obese tissue inhibitor of metalloproteinase-2 (TIMP-2)-deficient mice. Endocrinology. 2011 Apr.152(4):1300-1313. Pubmedid: 21285317. Pmcid: PMC3060627.
  • Villa J, Pratley RE. Ezetimibe/simvastatin or atorvastatin for the treatment of hypercholesterolemia in patients with the metabolic syndrome: the VYMET study. Curr Diab Rep. 2010 Jun.10(3):173-175. Pubmedid: 20425579.
  • Pratley RE. GIP: an inconsequential incretin or not?. Diabetes Care. 2010 Jul.33(7):1691-1692. Pubmedid: 20587731. Pmcid: PMC2890383.
  • Matfin G, Pratley RE. Advances in the treatment of prediabetes. Ther Adv Endocrinol Metab. 2010 Feb.1(1):5-14. Pubmedid: 23148144. Pmcid: PMC3474610.
  • Carlson A, Pratley RE. Weight loss and diets: which diet works best?. Curr Diab Rep. 2009 Feb.9(1):35-36. Pubmedid: 19192422.
  • Pratley RE. Overview of glucagon-like peptide-1 analogs and dipeptidyl peptidase-4 inhibitors for type 2 diabetes. Medscape J Med. 2008 Jul.10(7):171. Pubmedid: 18769687. Pmcid: PMC2525460.
  • Gilbert M, Pratley RE. LAP-BAND or medical therapy for metabolic syndrome?. Curr Diab Rep. 2008 Feb.8(1):5-6. Pubmedid: 18366991.
  • Nathan DM, Davidson MB, DeFronzo RA, Heine RJ, Henry RR, Pratley R, Zinman B. Impaired fasting glucose and impaired glucose tolerance: implications for care. Diabetes Care. 2007 Mar.30(3):753-759. Pubmedid: 17327355.
  • Salbe AD, DelParigi A, Pratley RE, Drewnowski A, Tataranni PA. Taste preferences and body weight changes in an obesity-prone population. Am J Clin Nutr. 2004 Mar.79(3):372-378. Pubmedid: 14985209.
  • Yang X, Pratley RE, Tokraks S, Tataranni PA, Permana PA. UCP5/BMCP1 transcript isoforms in human skeletal muscle: relationship of the short-insert isoform with lipid oxidation and resting metabolic rates. Mol Genet Metab. 2002 Apr.75(4):369-373. Pubmedid: 12051969.